STOCK TITAN
  1. Home
  2. News
  3. ARCT

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Arcturus Therapeutics (Nasdaq: ARCT), a commercial mRNA vaccines and medicines company, announced it will release its Q3 2024 financial results on November 7, 2024, after market close. The company will also host a conference call and webcast at 4:30 pm ET on the same day to discuss the results and provide a corporate update. The call can be accessed domestically at 1-800-274-8461 and internationally at 1-203-518-9814 using the conference ID: ARCTURUS. A webcast link will be available for streaming.

Arcturus Therapeutics (Nasdaq: ARCT), un'azienda commerciale di vaccini e medicinali mRNA, ha annunciato che rilascerà i suoi risultati finanziari del terzo trimestre 2024 il 7 novembre 2024, dopo la chiusura del mercato. L'azienda ospiterà anche una conference call e webcast alle 16:30 ET lo stesso giorno per discutere i risultati e fornire un aggiornamento aziendale. La chiamata sarà accessibile a livello nazionale al numero 1-800-274-8461 e a livello internazionale al numero 1-203-518-9814 utilizzando l'ID conferenza: ARCTURUS. Un link per la webcast sarà disponibile per lo streaming.

Arcturus Therapeutics (Nasdaq: ARCT), una empresa comercial de vacunas y medicamentos de ARNm, anunció que publicará sus resultados financieros del tercer trimestre de 2024 el 7 de noviembre de 2024, después del cierre del mercado. La empresa también realizará una conferencia telefónica y webcast a las 4:30 p.m. ET el mismo día para discutir los resultados y proporcionar una actualización corporativa. La llamada se podrá acceder a nivel nacional al 1-800-274-8461 y a nivel internacional al 1-203-518-9814 utilizando el ID de conferencia: ARCTURUS. Un enlace para la webcast estará disponible para transmisión.

Arcturus Therapeutics (Nasdaq: ARCT), 상업적인 mRNA 백신 및 의약품 회사는 2024년 3분기 재무 결과를 2024년 11월 7일, 시장 마감 후 발표할 것이라고 발표했습니다. 회사는 같은 날 오후 4시 30분 ET에 전화 회의 및 웹캐스트를 주최하여 결과를 논의하고 기업 업데이트를 제공할 예정입니다. 이 통화는 국내에서 1-800-274-8461로, 국제적으로는 1-203-518-9814로 접속할 수 있으며, 회의 ID는 ARCTURUS입니다. 웹캐스트 링크는 스트리밍을 위해 제공될 것입니다.

Arcturus Therapeutics (Nasdaq: ARCT), une entreprise commerciale de vaccins et de médicaments à ARNm, a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 le 7 novembre 2024, après la fermeture du marché. L'entreprise tiendra également une conférence téléphonique et un webinaire à 16h30 ET le même jour pour discuter des résultats et fournir une mise à jour de l'entreprise. L'appel pourra être accessible au niveau national au 1-800-274-8461 et au niveau international au 1-203-518-9814 en utilisant l'ID de conférence : ARCTURUS. Un lien de webinaire sera disponible pour le streaming.

Arcturus Therapeutics (Nasdaq: ARCT), ein Unternehmen für mRNA-Impfstoffe und -Medikamente, gab bekannt, dass es seine finanziellen Ergebnisse für das 3. Quartal 2024 am 7. November 2024, nach Börsenschluss, veröffentlichen wird. Das Unternehmen wird auch am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen und ein Unternehmensupdate zu geben. Die Konferenz kann national unter 1-800-274-8461 und international unter 1-203-518-9814 mit der Konferenz-ID: ARCTURUS erreicht werden. Ein Webcast-Link wird für das Streaming zur Verfügung stehen.

Positive
  • None.
Negative
  • None.

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA vaccines and medicines company focused on the development of infectious disease vaccines and addressing unmet medical needs within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended September 30, 2024 after the market close on Thursday, November 7 and will also host a conference call and webcast at 4:30 pm Eastern Time on November 7, 2024.

Arcturus Therapeutics Third Quarter 2024 Earnings Conference Call

  • Thursday, November 7, 2024 @ 4:30 p.m. ET
  • Domestic: 1-800-274-8461
  • International: 1-203-518-9814
  • Conference ID: ARCTURUS
  • Webcast: Link

About Arcturus

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus' pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

IR and Media Contacts

Arcturus Therapeutics

Neda Safarzadeh

VP, Head of IR/PR/Marketing

IR@arcturusrx.com

Source: Arcturus Therapeutics Holdings Inc.

FAQ

When will Arcturus Therapeutics report its Q3 2024 financial results?

Arcturus Therapeutics will report its Q3 2024 financial results on November 7, 2024, after market close.

What time is Arcturus Therapeutics' Q3 2024 earnings conference call?

The Q3 2024 earnings conference call for Arcturus Therapeutics will be at 4:30 pm ET on November 7, 2024.

How can I access the Arcturus Therapeutics Q3 2024 earnings conference call?

The call can be accessed domestically at 1-800-274-8461 and internationally at 1-203-518-9814 with the conference ID: ARCTURUS.

Will there be a webcast for Arcturus Therapeutics' Q3 2024 financial results?

Yes, a webcast link will be available for streaming the conference call.

Stock ARCT logo
Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

ARCT Rankings

#3126 Ranked by Market Cap
N/A Ranked by Dividends

ARCT Latest News

Sep 30, 2024
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
Sep 30, 2024
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
Sep 13, 2024
Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
Sep 13, 2024
Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
Sep 3, 2024
Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis

ARCT Stock Data

479.46M
27.04M
8.47%
93.19%
16.4%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO